222 related articles for article (PubMed ID: 19298219)
1. Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
Farias-Eisner R; Horblyuk R; Franklin M; Lunacsek OE; Happe LE
Curr Med Res Opin; 2009 May; 25(5):1081-7. PubMed ID: 19298219
[TBL] [Abstract][Full Text] [Related]
2. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients.
Dranitsaris G; Kahn SR; Stumpo C; Paton TW; Martineau J; Smith R; Ginsberg JS;
Am J Cardiovasc Drugs; 2004; 4(5):325-33. PubMed ID: 15449974
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism after total joint arthroplasty: results from a Japanese multicenter cohort study.
Migita K; Bito S; Nakamura M; Miyata S; Saito M; Kakizaki H; Nakayama Y; Matsusita T; Furuichi I; Sasazaki Y; Tanaka T; Yoshida M; Kaneko H; Abe I; Mine T; Ihara K; Kuratsu S; Saisho K; Miyahara H; Segata T; Nakagawa Y; Kamei M; Torigoshi T; Motokawa S
Arthritis Res Ther; 2014 Jul; 16(4):R154. PubMed ID: 25047862
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery.
Sullivan SD; Kwong L; Nutescu E
Value Health; 2006; 9(2):68-76. PubMed ID: 16626410
[TBL] [Abstract][Full Text] [Related]
6. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
7. Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery.
Changolkar A; Menditto L; Shah M; Puto K; Farrelly E
Am J Health Syst Pharm; 2014 Apr; 71(7):562-9. PubMed ID: 24644116
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Gordois A; Posnett J; Borris L; Bossuyt P; Jönsson B; Levy E; de Pouvourville G
J Thromb Haemost; 2003 Oct; 1(10):2167-74. PubMed ID: 14521600
[TBL] [Abstract][Full Text] [Related]
9. Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Annemans L; Minjoulat-Rey MC; De Knock M; Vranckx K; Czarka M; Gabriel S; Haentjens P
Acta Clin Belg; 2004; 59(6):346-57. PubMed ID: 15819379
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Sullivan SD; Davidson BL; Kahn SR; Muntz JE; Oster G; Raskob G
Pharmacoeconomics; 2004; 22(9):605-20. PubMed ID: 15209529
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
[TBL] [Abstract][Full Text] [Related]
13. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery.
Wade WE; Spruill WJ; Leslie RB
Am J Ther; 2004; 11(3):194-8. PubMed ID: 15133534
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
15. Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis.
Capri S; Ageno W; Imberti D; Palareti G; Piovella F; Scannapieco G; Moia M
Intern Emerg Med; 2010 Feb; 5(1):33-40. PubMed ID: 19890611
[TBL] [Abstract][Full Text] [Related]
16. Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Bjorvatn A; Kristiansen F
Am J Cardiovasc Drugs; 2005; 5(2):121-30. PubMed ID: 15725043
[TBL] [Abstract][Full Text] [Related]
17. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Happe LE; Farrelly EM; Stanford RH; Sarnes MW
J Thromb Thrombolysis; 2008 Oct; 26(2):125-31. PubMed ID: 18034323
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Radke OC; Kuhlisch E; Hartmann A; Weiss N; Werth S
J Thromb Haemost; 2012 Oct; 10(10):2045-52. PubMed ID: 22882706
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of fondaparinux versus enoxaparin for preventing venous thromboembolism after major orthopedic surgery: a meta-analysis].
Li H; Wang J; Xiao J; Shi Z
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Mar; 33(3):370-5. PubMed ID: 23529234
[TBL] [Abstract][Full Text] [Related]
20. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Turpie AG; Bauer KA; Eriksson BI; Lassen MR
Arch Intern Med; 2002 Sep; 162(16):1833-40. PubMed ID: 12196081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
